Mineralys Therapeutics
mineralystx.com
Actively hiring
Cardiometabolic Therapeutics
Prescription Drugs
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
How Mineralys Therapeutics hires
Truth index
A 95/100
Median time to fill
69 days
Ghost roles
0%
Stale roles
0%
Reposted roles
0%
Mineralys Therapeutics scores A on the Alion truth index (A is best, E worst), measured over 25 open roles re-checked against its own hiring board: 0% look like ghost listings, 0% have gone stale and 0% are the same role posted again. Its roles close in a median of 69 days. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed
Overview
Mineralys Therapeutics is a clinical-stage biopharmaceutical company that develops treatments for diseases driven by dysregulated aldosterone. Its lead candidate, lorundrostat, is an aldosterone synthase inhibitor studied in uncontrolled and resistant hypertension and chronic kidney disease, and the company is building commercial and manufacturing functions. The company is headquartered in Radnor, Pennsylvania, United States.
News
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing m...
Read more
Report
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension
The post Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension appeared first on Mineralys Therapeutics.
Read more
Report
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
The post Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension appeared first on Mineralys Therapeutics.
Read more
Report
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
The post First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor appeared first on Mineralys Therapeutics.
Read more
Report
Tech stack
Technologies named in job postings at Mineralys Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
4
Postings analysed
6
Stack modernity
74/100AI adopter
Languages
SAS
Developer tools
Microsoft Excel
AI & ML
Claude
LLM
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$193k
Typical range
$90k – $415k
Open positions
24
24
Jobs
Middle
41.7%
Senior
29.2%
Architect
29.2%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 10 | $165k | $165k |
| Senior | 7 | $225k | $90k – $415k |
| Architect | 7 | $220k | $195k – $275k |
Highest paying role
Senior Vice President, Regulatory Affairs
$415k
Normalized to USD per year
All salaries at Mineralys Therapeutics
By role, level and city, against the market · 24 jobs with pay
Growth
Hiring Momentum
67/100
Growing
Open positions
25
7 opened / 92 closed in 30 days
Median time-to-fill
69 days
faster than 19% of the market
ATS activity
Every ~3 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Early Careers
30% ▼
Legal
13% ▲
Sales
13% ▼
Leadership
9% ▲
Finance
9% ▼
Operations
9% ▲
Actively hiring for Legal (+3 in 30 days)
Activity Timeline
Added Agile to stack
Sep 2026
Added HIPAA to stack
Sep 2026
Added Microsoft Excel to stack
Sep 2026
Added SAS to stack
Sep 2026
Added X (Twitter) to stack
Sep 2026
Added LinkedIn to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Radnor
United States
HQ